Jazz Pharmaceuticals JAZZ Epilepsy — Revenue from Contract with Customer, Excluding Assessed Tax
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's epilepsy — revenue from contract with customer, excluding assessed tax.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's epilepsy — revenue from contract with customer, excluding assessed tax?
- Jazz Pharmaceuticals (JAZZ) reported epilepsy — revenue from contract with customer, excluding assessed tax of $249.8M in Q1 2026.
- What does epilepsy — revenue from contract with customer, excluding assessed tax mean?
- The total net sales revenue generated from the company's epilepsy-related pharmaceutical products.
- How do you interpret epilepsy — revenue from contract with customer, excluding assessed tax?
- An increase indicates growing market share, successful physician adoption, or expanded patient access for epilepsy therapies, while a decrease may signal increased competition, patent cliffs, or pricing pressure.
- How does epilepsy — revenue from contract with customer, excluding assessed tax compare across companies?
- Comparable to net product sales reported by other biopharmaceutical companies with specialized neurology or rare disease franchises, often benchmarked against total segment revenue growth rates.